

Jeanette H W Leusen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9566630/publications.pdf>

Version: 2024-02-01

126
papers

5,354
citations

76294

40
h-index

102432

66
g-index

131
all docs

131
docs citations

131
times ranked

7192
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis. <i>Cell Reports</i> , 2018, 23, 3946-3959.e6.	2.9	245
2	The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fc γ 3 Receptor α -Mediated Cross-Linking. <i>Journal of Immunology</i> , 2016, 197, 807-813.	0.4	225
3	Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. <i>Blood</i> , 2013, 122, 3482-3491.	0.6	206
4	Mac-1 (CD11b/CD18) is essential for Fc receptor α -mediated neutrophil cytotoxicity and immunologic synapse formation. <i>Blood</i> , 2001, 97, 2478-2486.	0.6	189
5	Crosstalk between Human IgG Isotypes and Murine Effector Cells. <i>Journal of Immunology</i> , 2012, 189, 3430-3438.	0.4	180
6	Glutaminy cyclase is an enzymatic modifier of the CD47- SIRP β axis and a target for cancer immunotherapy. <i>Nature Medicine</i> , 2019, 25, 612-619.	15.2	156
7	Functional Characteristics of the High Affinity IgG Receptor, Fc γ 3RI. <i>Journal of Immunology</i> , 2011, 186, 2699-2704.	0.4	152
8	<i>In vivo</i> Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling. <i>Cancer Research</i> , 2010, 70, 3209-3217.	0.4	125
9	Targeted Delivery of a Sialic Acid-Blocking Glycomimetic to Cancer Cells Inhibits Metastatic Spread. <i>ACS Nano</i> , 2015, 9, 733-745.	7.3	123
10	Effects of Bovine Immunoglobulins on Immune Function, Allergy, and Infection. <i>Frontiers in Nutrition</i> , 2018, 5, 52.	1.6	109
11	Interactions between the components of the human nadph oxidase: intrigues in the phox family. <i>Translational Research</i> , 1996, 128, 461-476.	2.4	107
12	Ig A antibodies mediate tumour killing <i>in vivo</i> . <i>EMBO Molecular Medicine</i> , 2013, 5, 1213-1226.	3.3	107
13	The High-Affinity IgG Receptor, Fc γ 3RI, Plays a Central Role in Antibody Therapy of Experimental Melanoma. <i>Cancer Research</i> , 2006, 66, 1261-1264.	0.4	98
14	The Fc γ 3RIa (CD64) Ligand Binding Chain Triggers Major Histocompatibility Complex Class II Antigen Presentation Independently of Its Associated FcR β -Chain. <i>Blood</i> , 1999, 94, 808-817.	0.6	97
15	The Importance of Human Fc γ 3RI in Mediating Protection to Malaria. <i>PLoS Pathogens</i> , 2007, 3, e72.	2.1	95
16	Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG. <i>Frontiers in Immunology</i> , 2019, 10, 704.	2.2	95
17	Mechanisms of action of CD20 antibodies. <i>American Journal of Cancer Research</i> , 2012, 2, 676-90.	1.4	88
18	Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. <i>MAbs</i> , 2014, 6, 1133-1144.	2.6	86

#	ARTICLE	IF	CITATIONS
19	Disturbed interaction of p21-rac with mutated p67-phox causes chronic granulomatous disease.. Journal of Experimental Medicine, 1996, 184, 1243-1249.	4.2	82
20	CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping. Cytometry Part B - Clinical Cytometry, 2019, 96, 134-142.	0.7	82
21	Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 8804-8809.	3.3	80
22	Interactions between the Cytosolic Components p47 and p67 of the Human Neutrophil NADPH Oxidase That Are Not Required for Activation in the Cell-free System. Journal of Biological Chemistry, 1995, 270, 11216-11221.	1.6	71
23	Cytolytic Mechanisms and Expression of Activation-Regulating Receptors on Effector-Type CD8+CD45RA+CD27+ Human T Cells. Journal of Immunology, 2000, 165, 1910-1917.	0.4	71
24	The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica, 2011, 96, 1822-1830.	1.7	69
25	Central Role of Complement in Passive Protection by Human IgG1 and IgG2 Anti-pneumococcal Antibodies in Mice. Journal of Immunology, 2003, 170, 6158-6164.	0.4	68
26	Mac-1 (CD11b/CD18) as Accessory Molecule for FcγR (CD89) Binding of IgA. Journal of Immunology, 2002, 169, 3831-3836.	0.4	64
27	Recombinant Dimeric IgA Antibodies against the Epidermal Growth Factor Receptor Mediate Effective Tumor Cell Killing. Journal of Immunology, 2011, 186, 3770-3778.	0.4	62
28	An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement <i>In Vivo</i>. Cancer Research, 2016, 76, 403-417.	0.4	57
29	IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47+ SIRPα Checkpoint Inhibition. Cancer Immunology Research, 2020, 8, 120-130.	1.6	57
30	Fc Receptor-Mediated Immunity Against Bordetella pertussis. Journal of Immunology, 2001, 167, 6545-6551.	0.4	55
31	Cytokine-induced immune complex binding to the high-affinity IgG receptor, Fcγ3RI, in the presence of monomeric IgG. Blood, 2010, 116, 5327-5333.	0.6	54
32	MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL. Cell Death and Disease, 2016, 7, e2345-e2345.	2.7	53
33	DC subset-specific induction of T cell responses upon antigen uptake via Fcγ3 receptors in vivo. Journal of Experimental Medicine, 2017, 214, 1509-1528.	4.2	53
34	IgA as therapeutic antibody. Molecular Immunology, 2015, 68, 35-39.	1.0	52
35	Contribution of Classic and Alternative Effector Pathways in Peanut-Induced Anaphylactic Responses. PLoS ONE, 2011, 6, e28917.	1.1	52
36	New insights in Type I and <sc>II CD</sc>20 antibody mechanisms of action with a panel of novel <sc>CD</sc>20 antibodies. British Journal of Haematology, 2018, 180, 808-820.	1.2	51

#	ARTICLE	IF	CITATIONS
37	Direct interaction between Fc γ RI (CD64) and periplakin controls receptor endocytosis and ligand binding capacity. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10392-10397.	3.3	49
38	γ 2T cell diversity and the receptor interface with tumor cells. Journal of Clinical Investigation, 2020, 130, 4637-4651.	3.9	49
39	Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting. MAbs, 2016, 8, 87-98.	2.6	47
40	<i>Staphylococcus aureus</i> Formyl Peptide Receptor-like 1 Inhibitor (FLIPr) and Its Homologue FLIPr-like Are Potent Fc γ RI Antagonists That Inhibit IgG-Mediated Effector Functions. Journal of Immunology, 2013, 191, 353-362.	0.4	46
41	Fc receptor inside-out signaling and possible impact on antibody therapy. Immunological Reviews, 2015, 268, 74-87.	2.8	46
42	Characterization of a Mutated IgA2 Antibody of the m(1) Allotype against the Epidermal Growth Factor Receptor for the Recruitment of Monocytes and Macrophages. Journal of Biological Chemistry, 2012, 287, 25139-25150.	1.6	44
43	Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness. Journal of Infectious Diseases, 2019, 219, 59-67.	1.9	42
44	Signaling through Mutants of the IgA Receptor CD89 and Consequences for Fc Receptor γ 3-Chain Interaction. Journal of Immunology, 2006, 176, 3603-3610.	0.4	40
45	Simultaneous Targeting of Fc γ Rs and Fc γ RI Enhances Tumor Cell Killing. Cancer Immunology Research, 2015, 3, 1316-1324.	1.6	40
46	Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice. Immunology Letters, 2012, 143, 44-52.	1.1	39
47	A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA. MAbs, 2016, 8, 74-86.	2.6	39
48	Clarifying the Confusion between Cytokine and Fc Receptor γ Common Gamma Chain \bullet Immunity, 2016, 45, 225-226.	6.6	37
49	Filamin A Stabilizes Fc γ RI Surface Expression and Prevents Its Lysosomal Routing. Journal of Immunology, 2008, 180, 3938-3945.	0.4	35
50	Cutting Edge: Fc γ RIII (CD16) and Fc γ RI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma. Journal of Immunology, 2012, 189, 5513-5517.	0.4	34
51	Aberrant Receptor-Mediated Endocytosis of <i>Schistosoma mansoni</i> Glycoproteins on Host Lipoproteins. PLoS Medicine, 2006, 3, e253.	3.9	33
52	Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. British Journal of Haematology, 2018, 181, 413-417.	1.2	33
53	Specificity and Effector Functions of Human RSV-Specific IgG from Bovine Milk. PLoS ONE, 2014, 9, e112047.	1.1	33
54	Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents. Antibodies, 2020, 9, 70.	1.2	32

#	ARTICLE	IF	CITATIONS
55	Serum Antibodies Critically Affect Virus-Specific CD4+/CD8+ T Cell Balance during Respiratory Syncytial Virus Infections. <i>Journal of Immunology</i> , 2010, 185, 6489-6498.	0.4	31
56	Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development. <i>Journal of Endotoxin Research</i> , 2004, 10, 113-119.	2.5	30
57	Fc γ RI (CD64) resides constitutively in lipid rafts. <i>Immunology Letters</i> , 2008, 116, 149-155.	1.1	30
58	Human IgG1 antibodies suppress angiogenesis in a target-independent manner. <i>Signal Transduction and Targeted Therapy</i> , 2016, 1, .	7.1	30
59	Fc γ RI ³ -Chain ITAM Signaling Is Critically Required for Cross-Presentation of Soluble Antibody-Antigen Complexes by Dendritic Cells. <i>Journal of Immunology</i> , 2014, 193, 5506-5514.	0.4	28
60	Mechanisms of inside-out signaling of the high-affinity IgG receptor Fc γ RI. <i>Science Signaling</i> , 2018, 11, .	1.6	28
61	Identification of a tumor-specific allo-HLA-restricted γ TCR. <i>Blood Advances</i> , 2019, 3, 2870-2882.	2.5	28
62	Inside-Out Regulation of Fc γ RI (CD89) Depends on PP2A. <i>Journal of Immunology</i> , 2008, 181, 4080-4088.	0.4	27
63	Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. , 2021, 9, e003000.		27
64	Anti-GM1 IgG antibodies induce leukocyte effector functions via Fc γ receptors. <i>Annals of Neurology</i> , 2003, 53, 570-579.	2.8	26
65	IgG Antibodies in Food Allergy Influence Allergen-Antibody Complex Formation and Binding to B Cells: A Role for Complement Receptors. <i>Journal of Immunology</i> , 2013, 191, 3526-3533.	0.4	26
66	Modulation of Fc γ RI (CD64) Ligand Binding by Blocking Peptides of Periplakin. <i>Journal of Biological Chemistry</i> , 2004, 279, 33875-33881.	1.6	24
67	Fc γ RI ³ -Chain Dependent Signaling in Immature Neutrophils Is Mediated by Fc γ RI, but Not by Fc γ RI ³ . <i>Journal of Immunology</i> , 2007, 179, 2918-2924.	0.4	24
68	Fc γ RIIIa genotype is associated with acute coronary syndromes as first manifestation of coronary artery disease. <i>Atherosclerosis</i> , 2009, 205, 512-516.	0.4	24
69	Daratumumab, a Human CD38 Antibody Induces Apoptosis of Myeloma Tumor Cells Via Fc Receptor-Mediated Crosslinking.. <i>Blood</i> , 2012, 120, 2974-2974.	0.6	24
70	Intravenous immune globulin suppresses angiogenesis in mice and humans. <i>Signal Transduction and Targeted Therapy</i> , 2016, 1, .	7.1	23
71	OS9 interacts with DC-STAMP and modulates its intracellular localization in response to TLR ligation. <i>Molecular Immunology</i> , 2009, 46, 505-515.	1.0	22
72	Immune Effector Functions of Human IgG2 Antibodies against EGFR. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 75-88.	1.9	22

#	ARTICLE	IF	CITATIONS
73	Complement receptor 3 mediates both sinking phagocytosis and phagocytic cup formation via distinct mechanisms. <i>Journal of Biological Chemistry</i> , 2021, 296, 100256.	1.6	22
74	Chronic bullous disease of childhood and a paecilomyces lung infection in chronic granulomatous disease. <i>Archives of Disease in Childhood</i> , 1997, 77, 150-152.	1.0	21
75	The alternatively spliced CD64 transcript Fc γ 3RIb2 does not specify a surface-expressed isoform. <i>European Journal of Immunology</i> , 1999, 29, 143-149.	1.6	20
76	A novel human CD32 mAb blocks experimental immune haemolytic anaemia in Fc γ RIIA transgenic mice. <i>British Journal of Haematology</i> , 2005, 130, 130-137.	1.2	20
77	Inhibition of the Classical and Lectin Pathway of the Complement System by Recombinant LAIR-2. <i>Journal of Innate Immunity</i> , 2014, 6, 284-292.	1.8	20
78	Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure. <i>Oncolimmunology</i> , 2022, 11, 2033528.	2.1	19
79	Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. <i>MAbs</i> , 2018, 10, 453-462.	2.6	17
80	Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 m(1) antibody. <i>MAbs</i> , 2013, 5, 936-945.	2.6	16
81	Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. <i>MAbs</i> , 2014, 6, 1300-1313.	2.6	16
82	Fc γ receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 918-920.	0.9	16
83	Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo. <i>MAbs</i> , 2021, 13, 1893888.	2.6	16
84	CpG oligodeoxynucleotides enhance Fc γ RI-mediated cross presentation by dendritic cells. <i>International Immunology</i> , 2004, 16, 1091-1098.	1.8	15
85	A novel Fc γ RIIIa Q27W gene variant is associated with common variable immune deficiency through defective Fc γ RIIIa downstream signaling. <i>Clinical Immunology</i> , 2014, 155, 108-117.	1.4	15
86	Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics. <i>PLoS ONE</i> , 2015, 10, e0130829.	1.1	15
87	Protein 4.1G binds to a unique motif within the Fc γ RI cytoplasmic tail. <i>Molecular Immunology</i> , 2008, 45, 2069-2075.	1.0	14
88	Bivalent binding on cells varies between anti-CD20 antibodies and is dose-dependent. <i>MAbs</i> , 2020, 12, 1792673.	2.6	14
89	Flow cytometric determination of Fc γ RIIIa (CD32) polymorphism. <i>Journal of Immunological Methods</i> , 2004, 294, 135-144.	0.6	13
90	Direct targeting of genetically modified tumour cells to Fc γ RI triggers potent tumour cytotoxicity. <i>British Journal of Haematology</i> , 2006, 132, 317-325.	1.2	13

#	ARTICLE	IF	CITATIONS
91	Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering. <i>Science Advances</i> , 2019, 5, eaaw1822.	4.7	13
92	FcγRI Dynamics Are Regulated by GSK-3 and PKCθ During Cytokine Mediated Inside-Out Signaling. <i>Frontiers in Immunology</i> , 2019, 9, 3191.	2.2	13
93	Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies. <i>MAbs</i> , 2020, 12, 1795505.	2.6	13
94	Bovine IgG Prevents Experimental Infection With RSV and Facilitates Human T Cell Responses to RSV. <i>Frontiers in Immunology</i> , 2020, 11, 1701.	2.2	13
95	Role of Leukocyte Immunoglobulin G Receptors in Vaccine-Induced Immunity to <i>Streptococcus pneumoniae</i> . <i>Journal of Infectious Diseases</i> , 2003, 187, 1686-1693.	1.9	12
96	Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcγRI transgenic mice. <i>Immunology Letters</i> , 2014, 160, 151-157.	1.1	12
97	Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions. <i>Cancer Science</i> , 2021, 112, 3029-3040.	1.7	11
98	Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma. , 2021, 9, e003163.		11
99	Antibody-catalyzed water oxidation: state-of-the-art immunity or ancient history?. <i>Trends in Immunology</i> , 2003, 24, 467-469.	2.9	10
100	The Fcγ3 receptor IIA R131H gene polymorphism is associated with endothelial function in patients with hypercholesterolaemia. <i>Atherosclerosis</i> , 2011, 218, 411-415.	0.4	10
101	Patients with unstable angina pectoris show an increased frequency of the Fc gamma RIIa R131 allele. <i>Autoimmunity</i> , 2012, 45, 556-564.	1.2	10
102	A novel polymorphism in the coding region of CYBB, the human gp91-phox gene. <i>Human Genetics</i> , 1996, 97, 611-613.	1.8	9
103	Boosting antibody therapy with complement. <i>Blood</i> , 2012, 119, 5945-5947.	0.6	9
104	Human amniotic fluid antibodies protect the neonate against respiratory syncytial virus infection. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1477-1480.e5.	1.5	9
105	The selection of variable regions affects effector mechanisms of IgA antibodies against CD20. <i>Blood Advances</i> , 2021, 5, 3807-3820.	2.5	9
106	Biological Validation of Plant-derived Anti-human Colorectal Cancer Monoclonal Antibody CO17-1A. <i>Hybridoma</i> , 2009, 28, 7-12.	0.5	8
107	c-Jun activating binding protein 1 binds to the IgA receptor and modulates protein levels of FcγRI and FcRI3α chain. <i>European Journal of Immunology</i> , 2010, 40, 2035-2040.	1.6	8
108	Single Nucleotide Polymorphisms of the High Affinity IgG Receptor FcγRI Reduce Immune Complex Binding and Downstream Effector Functions. <i>Journal of Immunology</i> , 2017, 199, 2432-2439.	0.4	8

#	ARTICLE	IF	CITATIONS
109	The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opinion on Biological Therapy, 2018, 18, 973-982.	1.4	7
110	Evaluation of immunotherapies improving macrophage anti-tumor response using a microfluidic model. Organs-on-a-Chip, 2022, 4, 100019.	1.8	7
111	Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?. Frontiers in Immunology, 0, 13, .	2.2	7
112	Targeting the high affinity receptor, Fc γ RI, in autoimmune disease, neuropathy, and cancer. Immunotherapy Advances, 2022, 2, .	1.2	6
113	Association of the leukocyte immunoglobulin G (Fc γ) receptor IIIa ϵ 158V/F polymorphism with inflammatory myopathies in Dutch patients. Tissue Antigens, 2009, 73, 586-589.	1.0	5
114	Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells". Journal of Immunology, 2018, 200, 2515-2516.	0.4	3
115	Expression of CD64 (Fc γ RI) in skin of patients with acute GVHD. Bone Marrow Transplantation, 2011, 46, 1566-1569.	1.3	2
116	CD20 Antibodies of Human IgA Isotype Mediate CDC, and ADCC By Myeloid Effector Cells. Blood, 2016, 128, 1835-1835.	0.6	2
117	The Role of IgG in Immune Responses. , 2013, , 85-112.		1
118	Meeting Report on Immunoreceptors 2014. FASEB Journal, 2015, 29, 740-744.	0.2	1
119	Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components: the PRIMA birth cohort. BMC Infectious Diseases, 2022, 22, 152.	1.3	1
120	A novel polymorphism in the coding region of CYBB, the human gp91-phox gene. Human Genetics, 1996, 97, 611-613.	1.8	1
121	Correction: Cutting Edge: Fc γ RIII (CD16) and Fc γ RI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma. Journal of Immunology, 2013, 190, 1381-1381.	0.4	0
122	Recombinant Dimeric IgA Antibodies as Tumor-Specific Agents.. Blood, 2010, 116, 1488-1488.	0.6	0
123	Glycoengineered CD20 Antibody Obinutuzumab Activates Neutrophils and Mediates Phagocytosis Through CD16B More Efficiently Than Rituximab. Blood, 2013, 122, 4419-4419.	0.6	0
124	Pharmacokinetics and myeloid effector cell engagement of an engineered IgA antibody against the epidermal growth factor receptor.. Journal of Clinical Oncology, 2015, 33, 3037-3037.	0.8	0
125	Complement receptor 3 mediates both sinking phagocytosis and phagocytic cup formation via distinct mechanisms. Journal of Biological Chemistry, 2021, , .	1.6	0
126	Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMABA $\text{\textcircled{R}}$. Biomedicine and Pharmacotherapy, 2022, 151, 113090.	2.5	0